Open AccessJab1 (COPS5) as an Emerging Prognostic, Diagnostic and Therapeutic Biomarker for Human Cancer
Author(s) -
Pratibha Pandey,
Fahad Khan,
Rashmi Mishra,
Rekha Singh,
Tarun Kumar Upadhyay,
Sujeet Kumar Singh
Publication year - 2021
Publication title -
biointerface research in applied chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.216
H-Index - 11
ISSN - 2069-5837
DOI - 10.33263/briac125.70017011
Subject(s) - carcinogenesis , cancer research , cancer , dna damage , cell growth , biology , tumor progression , signal transduction , metastasis , cell cycle , suppressor , genome instability , apoptosis , biomarker , cancer cell , microbiology and biotechnology , dna , genetics
Jab1 (C-Jun activation domain-binding protein-1) has been reported to be critically involved in regulating apoptosis, cell proliferation, cell cycle, thereby affecting numerous pathways, DDR (DNA damage response) regulation, and genomic instability. Jab1 (CSN5) dysregulation has been positively associated with oncogenesis via activating oncogenes and deactivating various tumor suppressors. Jab1 overexpression has been reported in several tumor forms, illuminating its potent efficacy in cancer progression and metastasis. Jab1 has instigated prompt research interest in elucidating inhibitors of numerous oncoproteins and oncogenes for chemotherapeutics. Our review has presented strong evidence for presenting the significance of Jab1 overexpression in numerous carcinomas and its involvement in modulating various signaling pathways for cancer cell survival. This review may project a new way for utilizing Jab1 as a strong target for developing potent inhibitory compounds targeting Jab1 that could be further utilized in chemoprevention with limited side effects. Altogether this review further confirmed the crucial involvement of Jab1 in carcinogenesis and tumorigenesis, displaying the strong potential of Jab1 as one of the potent cancer biomarkers.